GEN1d
C3i Center Receives EMA Approval to Manufacture Cell Therapy Products for Europe
C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.
Canadian Manufacturing1d
C3i to manufacture cell therapy products for European market
MONTRÉAL — C3i Center obtains regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the European market. C3i, therefore, obtains a certificate of GMP ...
Centre C3i Inc.: C3i Center, a Canadian company, receives approval from the EMA to manufacture cell therapy products for the European market
The company received a certificate of Good Manufacturing Practice (GMP) compliance following an inspection of their Montreal facility by the European Medicines AgencyMONTRÉAL, Feb. 19, 2025 (GLOBE NEW ...
Le Lézard1d
C3i Center, a Canadian company, receives approval from the EMA to manufacture cell therapy products for the European market
C3i Center (C3i) announces that it has obtained regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the European market. C3i, therefore, obtains a ...
HYTN Launches GMP Stability Program and Validates Vape Cartridges for International Markets
The Stability Program is being conducted in collaboration with HYTN’s GMP-licensed laboratory partner. Upon successful completion, HYTN expects to provide an initial six-month stability statement for ...
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript February 13, 2025 Applied DNA Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0.32. Operator: Good day, and welcome to ...